The Albert B Sabin Vaccine Institute Inc
- Assets
- $21.7m
- Revenue
- $33.5m
- Investments
- $0.0
- Employees
- 78
- Location
- Washington, DC
- Founding
- 10/1994
- Data as of
- 12/2022
- EIN
- 06-1389829
Organization Overview
The Albert B Sabin Vaccine Institute Inc is located in Washington, DC. The organization was established in 1994. According to its NTEE Classification (Z99) the organization is classified as: Unknown, under the broad grouping of Unknown and related organizations. As of 12/2022, Albert B Sabin Vaccine Institute Inc employed 78 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Albert B Sabin Vaccine Institute Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Albert B Sabin Vaccine Institute Inc generated $33.5m in total revenue. This represents relatively stable growth, over the past 8 years the organization has increased revenue by an average of 8.1% each year. All expenses for the organization totaled $31.3m during the year ending 12/2022. While expenses have increased by 6.5% per year over the past 8 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Albert B Sabin Vaccine Institute Inc has awarded 47 individual grants totaling $13,144,953. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
TO MAKE VACCINES MORE ACCESSIBLE, ENABLE INNOVATION AND EXPAND IMMUNIZATION.
Describe the Organization's Program Activity:
Part 3 - Line 4a
VACCINE RESEARCH & DEVELOPMENTTHE SABIN VACCINE INSTITUTE SUPPORTS INNOVATIVE TECHNOLOGIES AND APPROACHES IN VACCINE RESEARCH AND DEVELOPMENT TO COMBAT INFECTIOUS AND EMERGING THREATS TO GLOBAL HEALTH. SABIN'S RESEARCH & DEVELOPMENT STRATEGY IS TO PRIORITIZE STRONG VACCINE CANDIDATES THAT LACK COMMERCIAL VALUE, TARGETING DISEASES THAT IMPACT THE WORLD'S MOST VULNERABLE POPULATIONS. SABIN LEVERAGES THE EXPERTISE OF PARTNERS IN THE ACADEMIC, PUBLIC, AND PRIVATE SECTORS, AND PROMOTES OPEN-SOURCE RESEARCH.EBOLA HAS TAKEN THE LIVES OF NEARLY 14,000 PEOPLE DURING THE LAST DECADE. TO PROTECT COMMUNITIES ACROSS THE GLOBE FROM THE CRITICAL THREAT POSED BY EBOLA AND THE CLOSELY RELATED, BUT LESSER KNOWN, MARBURG VIRUS, SABIN IS CURRENTLY DEVELOPING VACCINES FOR SUDAN EBOLAVIRUS AND MARBURG VIRUS DISEASES BASED ON TECHNOLOGY LICENSED FROM GSK. THE PROPHYLACTIC VACCINE CANDIDATES ARE BASED ON GSK'S PROPRIETARY CHAD3 PLATFORM. IN 2019, THE U.S. HEALTH AND HUMAN SERVICES' BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY AWARDED SABIN A MULTI-YEAR DEVELOPMENT CONTRACT TO ADVANCE DEVELOPMENT OF THE MARBURG AND SUDAN EBOLAVIRUS VACCINES
GLOBAL IMMUNIZATIONDESPITE SCIENTIFIC ADVANCES AND INTERNATIONAL SUPPORT, 1.5 MILLION PEOPLE STILL DIE EACH YEAR FROM DISEASES THAT COULD HAVE BEEN PREVENTED BY IMMUNIZATION. SABIN'S GLOBAL IMMUNIZATION ARM FOCUSES ON IMPROVING VACCINE DISTRIBUTION, INCREASING UPTAKE, AND DRIVING MORE EQUITABLE ACCESS TO VACCINATION SERVICES. SABIN WORKS ON THESE GOALS WITH A MULTI-LAYERED PROGRAMMATIC APPROACH INCLUDING: ADVANCING RESEARCH TO UNDERSTAND THE SOCIAL AND BEHAVIORAL DRIVERS FOR VACCINE ACCEPTANCE AND DEMAND; FOSTERING PEER TO PEER COLLABORATION ON IMMUNIZATION AND BUILDING CAPACITY AND LEADERSHIP SKILLS FOR IMMUNIZATION PROFESSIONALS; COALESCING MULTI-SECTORAL PARTNERS AND COMMUNITY LEADERS AND INFLUENCERS TO SUPPORT THE INTRODUCTION AND EXPANSION OF NEW AND UNDER-UTILIZED VACCINES SUCH AS THE HPV VACCINE; AND GENERATING ESSENTIAL EPIDEMIOLOGICAL DATA TO INFORM IMMUNIZATION POLICY AND IMPLEMENTATION DECISIONS FOR DISEASES SUCH AS TYPHOID.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Adegbola Richard Trustee | Trustee | 2 | $0 |
Baylor Norman Trustee | Trustee | 2 | $0 |
Commins Holman Wendy Trustee | Trustee | 2 | $0 |
Djibo Yacine Trustee | Trustee | 2 | $0 |
Fox Elizabeth Trustee | Trustee | 2 | $0 |
Hoos Axel Trustee | Trustee | 2 | $0 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Reithera Srl Bulk Drug Substance Production For Ebola | 12/30/22 | $8,167,000 |
Texas Biomedical Research Institute Immunogenicity And Efficacy Testing For | 12/30/22 | $3,328,787 |
Batelle Memorial Institute Clinical Trial Tests For R&d Program | 12/30/22 | $1,233,627 |
Bdo Usa Llp Financial And Quality Management For R&d | 12/30/22 | $1,219,135 |
Ppd Development Regulatory Support Services And Clinical | 12/30/22 | $397,571 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $21,463,101 |
| All other contributions, gifts, grants, and similar amounts not included above | $12,004,135 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $33,467,236 |
| Total Program Service Revenue | $0 |
| Investment income | $64,893 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $13,274 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $33,545,403 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $1,073,909 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $2,054,039 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $882,890 |
| Compensation of current officers, directors, key employees. | $125,967 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $5,710,335 |
| Pension plan accruals and contributions | $77,579 |
| Other employee benefits | $661,020 |
| Payroll taxes | $451,442 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $132,811 |
| Fees for services: Accounting | $21,708 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $17,317,875 |
| Advertising and promotion | $467,388 |
| Office expenses | $102,913 |
| Information technology | $84,088 |
| Royalties | $0 |
| Occupancy | $268,707 |
| Travel | $550,586 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $543,859 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $399,187 |
| Insurance | $241,223 |
| All other expenses | $0 |
| Total functional expenses | $31,282,727 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $1,506,086 |
| Savings and temporary cash investments | $7,361,995 |
| Pledges and grants receivable | $9,587,532 |
| Accounts receivable, net | $89,556 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $506,438 |
| Net Land, buildings, and equipment | $730,567 |
| Investments—publicly traded securities | $444,763 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $1,201,953 |
| Other assets | $275,785 |
| Total assets | $21,704,675 |
| Accounts payable and accrued expenses | $5,814,295 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $1,536,096 |
| Total liabilities | $7,350,391 |
| Net assets without donor restrictions | $4,311,941 |
| Net assets with donor restrictions | $10,042,343 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $21,704,675 |
Grants Awarded
Over the last fiscal year, The Albert B Sabin Vaccine Institute Inc has awarded $1,073,909 in support to 9 organizations.
| Grant Recipient | Amount |
|---|---|
AIDS VACCINE ADVOCACY COALITION PURPOSE: Vaccine Acceptance research site | $75,452 |
INTERNATIONAL WOMEN'S MEDIA FOUNDATION PURPOSE: Vaccine Acceptance journalist mentoring grant | $112,500 |
JOHNS HOPKINS UNIVERSITY PURPOSE: Vaccine Acceptance research site | $142,297 |
LOMA LINDA UNIVERSITY CASH CONCENTRATION PURPOSE: Vaccine Acceptance Small Grants Program awardee | $44,267 |
MASSACHUSETTS GENERAL HOSPITAL PURPOSE: Epidemiology study site | $145,963 |
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA PURPOSE: Vaccine Acceptance Small Grants Program awardee | $39,930 |